NEW ORLEANS, May 20, 2023 /PRNewswire/ -- Abbott today announced late-breaking results from the AVEIR™ dual-chamber (DR) i2i™ Investigational Device Exemption (IDE) study, a large-scale study to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results